0000000000042881

AUTHOR

Elisabetta Zulato

0000-0002-2624-5060

showing 3 related works from this author

Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.

2011

Abstract VEGF antagonists are now widely used cancer therapeutics, but predictive biomarkers of response or toxicity remain unavailable. In this study, we analyzed the effects of anti-VEGF therapy on tumor metabolism and therapeutic response by using an integrated set of imaging techniques, including bioluminescence metabolic imaging, 18-fluorodeoxyglucose positron emission tomography, and MRI imaging and spectroscopy. Our results revealed that anti-VEGF therapy caused a dramatic depletion of glucose and an exhaustion of ATP levels in tumors, although glucose uptake was maintained. These metabolic changes selectively accompanied the presence of large necrotic areas and partial tumor regress…

Vascular Endothelial Growth Factor ACancer Researchmedicine.medical_specialtyMagnetic Resonance SpectroscopyGlucose uptakeBiologyMiceFluorodeoxyglucose F18Internal medicineCell Line TumormedicineAnimalsHumansGlycolysisViability assayProtein kinase AAdenylate KinaseAMPKCancerNeoplasms Experimentalmedicine.diseaseWarburg effectMagnetic Resonance ImagingEndocrinologyPhenotypeOncologyCancer researchTumor necrosis factor alphaGlycolysisCancer research
researchProduct

VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells

2014

Abstract Anti-VEGF therapy perturbs tumor metabolism, severely impairing oxygen, glucose, and ATP levels. In this study, we investigated the effects of anti-VEGF therapy in multiple experimental tumor models that differ in their glycolytic phenotypes to gain insights into optimal modulation of the metabolic features of this therapy. Prolonged treatments induced vascular regression and necrosis in tumor xenograft models, with highly glycolytic tumors becoming treatment resistant more rapidly than poorly glycolytic tumors. By PET imaging, prolonged treatments yielded an increase in both hypoxic and proliferative regions of tumors. A selection for highly glycolytic cells was noted and this met…

Vascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyNecrosismedicine.medical_treatmentAngiogenesis InhibitorsMice SCIDBiologySCIDAntibodies Monoclonal HumanizedAntibodiesCell LineTargeted therapyMiceRandom AllocationCell Line TumorNeoplasmsMonoclonalAngiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Bevacizumab; Cell Line Tumor; Female; Glycolysis; Humans; MCF-7 Cells; Mice; Mice Inbred BALB C; Mice SCID; Molecular Targeted Therapy; Neoplasms; Phenotype; Random Allocation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor AssaysmedicineAnimalsHumansGlycolysisMolecular Targeted Therapycancer-cellAnti-VEGF therapyHumanizedInbred BALB CMED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAMice Inbred BALB CTumorpositron emission tomography antiangiogenesis glucose metabolism hypoxiaXenograft Model Antitumor AssaysPhenotypeBlockadeBevacizumabVascular endothelial growth factor APhenotypeOncologyCell cultureMonoclonalMCF-7 CellsCancer researchMED/06 - ONCOLOGIA MEDICAFemalemedicine.symptomGlycolysis
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct